Table 10.
Liquid biopsy in circulatory system cancers
| Cancer | Liquid biomarker | Origin | Tendency | Downstream target | Function | Reference |
|---|---|---|---|---|---|---|
| MDS/AML | ctDNA | Plasma | up | Disease progression biomarker | 382 | |
| ctDNA | Serum | up | Prognostic biomarker | 389 | ||
| cfDNA | Plasma | up | Disease progression biomarker | 383 | ||
| cfDNA mutation | Plasma, Serum | up | Disease progression biomarker | 385 | ||
| ctDNA methylation | Peripheral blood | up | Early diagnostic biomarker, Efficacy monitoring biomarker | 384 | ||
| Lymphoma | ctDNA | Serum | up | Disease progression biomarker, Efficacy monitoring biomarker | 392 | |
| ctDNA mutation | Peripheral blood | up | Disease progression biomarker | 395 | ||
| ctDNA | Peripheral blood | up | Early diagnostic biomarker, Efficacy monitoring biomarker | 396 | ||
| ctDNA mutation | Peripheral blood | up | Efficacy monitoring biomarker | 397 | ||
| ctDNA | Plasma | up | Efficacy monitoring biomarker | 399 | ||
| MM | CTCs | Peripheral blood | up | Early diagnostic biomarker | 403 | |
| ctDNA | Plasma | up | Disease progression biomarker | 407 | ||
| cfDNA | Plasma | up | Early diagnostic biomarker | 408 | ||
| ctDNA mutation | Serum | up | Disease progression biomarker | 405 | ||
| FGFR3, KMT2C, MAML2, ZFHX4 mutation | Peripheral blood | up | Efficacy monitoring biomarker | 409 |